Ascletis Pharma Inc. (1672.HK)

HKD 6.43

(4.55%)

Total Liabilities Summary of Ascletis Pharma Inc.

Ascletis Pharma Inc.'s latest annual total liabilities in 2023 was 148.94 Million CNY , up 27.13% from previous year.
Ascletis Pharma Inc.'s latest quarterly total liabilities in 2024 Q2 was 95.79 Million CNY , down 0.0% from previous quarter.
Ascletis Pharma Inc. reported annual total liabilities of 117.15 Million CNY in 2022, up 16.13% from previous year.
Ascletis Pharma Inc. reported annual total liabilities of 100.88 Million CNY in 2021, up 18.1% from previous year.
Ascletis Pharma Inc. reported quarterly total liabilities of 95.79 Million CNY for 2024 Q1, down -35.69% from previous quarter.
Ascletis Pharma Inc. reported quarterly total liabilities of 90.78 Million CNY for 2023 Q1, down -22.51% from previous quarter.

Annual Total Liabilities Chart of Ascletis Pharma Inc. (2023 - 2016)

Historical Annual Total Liabilities of Ascletis Pharma Inc. (2023 - 2016)

Year	Total Liabilities	Total Liabilities Growth
2023	148.94 Million CNY	27.13%
2022	117.15 Million CNY	16.13%
2021	100.88 Million CNY	18.1%
2020	85.42 Million CNY	-16.39%
2019	102.17 Million CNY	1.98%
2018	100.19 Million CNY	-17.49%
2017	121.42 Million CNY	-4.53%
2016	127.18 Million CNY	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	95.79 Million CNY	0.0%
2024 Q1	95.79 Million CNY	-35.69%
2023 Q1	90.78 Million CNY	-22.51%
2023 FY	148.94 Million CNY	27.13%
2023 Q4	148.94 Million CNY	0.0%
2023 Q3	148.94 Million CNY	64.06%
2023 Q2	90.78 Million CNY	0.0%
2022 Q3	117.15 Million CNY	7.59%
2022 Q2	108.89 Million CNY	0.0%
2022 Q1	108.89 Million CNY	7.94%
2022 Q4	117.15 Million CNY	0.0%
2022 FY	117.15 Million CNY	16.13%
2021 FY	100.88 Million CNY	18.1%
2021 Q3	100.88 Million CNY	28.34%
2021 Q4	100.88 Million CNY	0.0%
2021 Q1	78.61 Million CNY	-7.97%
2021 Q2	78.61 Million CNY	0.0%
2020 Q2	81.65 Million CNY	0.0%
2020 Q3	85.42 Million CNY	4.62%
2020 Q4	85.42 Million CNY	0.0%
2020 Q1	81.65 Million CNY	-20.08%
2020 FY	85.42 Million CNY	-16.39%
2019 Q1	82.64 Million CNY	-11.52%
2019 FY	102.17 Million CNY	1.98%
2019 Q4	102.17 Million CNY	0.0%
2019 Q3	102.17 Million CNY	23.62%
2019 Q2	82.64 Million CNY	0.0%
2018 Q1	89.96 Million CNY	-9.33%
2018 FY	100.19 Million CNY	-17.49%
2018 Q4	93.4 Million CNY	0.0%
2018 Q3	93.4 Million CNY	-19.64%
2018 Q2	116.23 Million CNY	29.19%
2017 FY	121.42 Million CNY	-4.53%
2017 Q1	- CNY	0.0%
2017 Q3	99.22 Million CNY	0.0%
2017 Q4	99.22 Million CNY	0.0%
2016 FY	127.18 Million CNY	0.0%

Peer Total Liabilities Comparison of Ascletis Pharma Inc.

Name	Total Liabilities	Total Liabilities Difference
Uni-Bio Science Group Limited	152.81 Million HKD	2.536%
CK Life Sciences Int'l., (Holdings) Inc.	7.05 Billion HKD	97.89%